Digoxin levels need to be monitored closely when the following medication is started:
1. Loratadine
2. Diphenhydramine
3. Ipratropium
4. Albuterol
Patients with pheochromocytoma should avoid which of the following classes of drugs because
of the possibility of developing hypertensive crisis?
1. Expectorants
2. Beta-2-agonists
3. Antitussives
4. Antihistamines
A patient has been prescribed silver sulfadiazine (Silvadene) cream to treat burns on his leg.
Normal adverse effects of silver sulfadiazine cream include:
1. Transient leukopenia on days 2 to 4 that should resolve
2. Worsening of burn symptoms briefly before resolution
3. A red, scaly rash that will resolve with continued use
4. Hypercalcemia
Long-acting beta-agonists (LTBAs) received a Black Box Warning from the U.S. Food and Drug
Administration due to the:
1. Risk of life-threatening dermatological reactions
2. Increased incidence of cardiac events when LTBAs are used
3. Increased risk of asthma-related deaths when LTBAs are used
4. Risk for life-threatening alterations in electrolytes
*********** ASTHMA ***********************
Harold, a 42-year-old African American, has moderate persistent asthma. Which of the
following asthma medications should be used cautiously, if at all?
1. Betamethasone, an inhaled corticosteroid
2. Salmeterol, an inhaled long-acting beta-agonist
3. Albuterol, a short-acting beta-agonist
4. Montelukast, a leukotriene modifier
Prior to developing a plan for the treatment of asthma, the patient's asthma should be classified
according to the NHLBI Expert Panel 3 guidelines. In adults mild-persistent asthma is classified
as asthma symptoms that occur:
1. Daily
2. Daily and limit physical activity
3. Less than twice a week
4. More than twice a week and less than once a day
In children age 5 to 11 years mild-persistent asthma is diagnosed when asthma symptoms occur:
1. At nighttime one to two times a month
2. At nighttime three to four times a month
3. Less than twice a week
4. Daily
, One goal of asthma therapy outlined by the NHLBI Expert Panel 3 guidelines is:
1. Ability to use albuterol daily to control symptoms
2. Minimize exacerbations to once a month
3. Keep nighttime symptoms at a maximum of twice a week
4. Require infrequent use of beta 2 agonists (albuterol) for relief of symptoms
A stepwise approach to the pharmacologic management of asthma:
1. Begins with determining the severity of asthma and assessing asthma control
2. Is used when asthma is severe and requires daily steroids
3. Allows for each provider to determine their personal approach to the care of asthmatic patients
4. Provides a framework for the management of severe asthmatics, but is not as helpful when
patients have intermittent asthma
Treatment for mild intermittent asthma is:
1. Daily inhaled medium-dose corticosteroids
2. Short-acting beta-2-agonists (albuterol) as needed
3. Long-acting beta-2-agonists every morning as a preventative
4. Montelukast (Singulair) daily
The first-line therapy for mild-persistent asthma is:
1. High-dose montelukast
2. Theophylline
3. Low-dose inhaled corticosteroids
4. Long-acting beta-2-agonists
Monitoring a patient with persistent asthma includes:
1. Monitoring how frequently the patient has an upper respiratory infection (URI) during
treatment
2. Monthly in-office spirometry testing
3. Determining if the patient has increased use of his or her long-acting beta-2-agonist due to
exacerbations
4. Evaluating the patient every 1 to 6 months to determine if the patient needs to step up or
down in their therapy
Asthma exacerbations at home are managed by the patient by:
1. Increasing frequency of beta-2-agonists and contacting their provider
2. Doubling inhaled corticosteroid doses
3. Increasing frequency of beta-2-agonists
4. Starting montelukast (Singulair)
Patients who are at risk of a fatal asthma attack include patients:
1. With moderate persistent asthma
2. With a history of requiring intubation or ICU admission for asthma
3. Who are on daily inhaled corticosteroid therapy
4. Who are pregnant
Pregnant patients with asthma may safely use ________ throughout their pregnancy.
1. Oral terbutaline
1. Loratadine
2. Diphenhydramine
3. Ipratropium
4. Albuterol
Patients with pheochromocytoma should avoid which of the following classes of drugs because
of the possibility of developing hypertensive crisis?
1. Expectorants
2. Beta-2-agonists
3. Antitussives
4. Antihistamines
A patient has been prescribed silver sulfadiazine (Silvadene) cream to treat burns on his leg.
Normal adverse effects of silver sulfadiazine cream include:
1. Transient leukopenia on days 2 to 4 that should resolve
2. Worsening of burn symptoms briefly before resolution
3. A red, scaly rash that will resolve with continued use
4. Hypercalcemia
Long-acting beta-agonists (LTBAs) received a Black Box Warning from the U.S. Food and Drug
Administration due to the:
1. Risk of life-threatening dermatological reactions
2. Increased incidence of cardiac events when LTBAs are used
3. Increased risk of asthma-related deaths when LTBAs are used
4. Risk for life-threatening alterations in electrolytes
*********** ASTHMA ***********************
Harold, a 42-year-old African American, has moderate persistent asthma. Which of the
following asthma medications should be used cautiously, if at all?
1. Betamethasone, an inhaled corticosteroid
2. Salmeterol, an inhaled long-acting beta-agonist
3. Albuterol, a short-acting beta-agonist
4. Montelukast, a leukotriene modifier
Prior to developing a plan for the treatment of asthma, the patient's asthma should be classified
according to the NHLBI Expert Panel 3 guidelines. In adults mild-persistent asthma is classified
as asthma symptoms that occur:
1. Daily
2. Daily and limit physical activity
3. Less than twice a week
4. More than twice a week and less than once a day
In children age 5 to 11 years mild-persistent asthma is diagnosed when asthma symptoms occur:
1. At nighttime one to two times a month
2. At nighttime three to four times a month
3. Less than twice a week
4. Daily
, One goal of asthma therapy outlined by the NHLBI Expert Panel 3 guidelines is:
1. Ability to use albuterol daily to control symptoms
2. Minimize exacerbations to once a month
3. Keep nighttime symptoms at a maximum of twice a week
4. Require infrequent use of beta 2 agonists (albuterol) for relief of symptoms
A stepwise approach to the pharmacologic management of asthma:
1. Begins with determining the severity of asthma and assessing asthma control
2. Is used when asthma is severe and requires daily steroids
3. Allows for each provider to determine their personal approach to the care of asthmatic patients
4. Provides a framework for the management of severe asthmatics, but is not as helpful when
patients have intermittent asthma
Treatment for mild intermittent asthma is:
1. Daily inhaled medium-dose corticosteroids
2. Short-acting beta-2-agonists (albuterol) as needed
3. Long-acting beta-2-agonists every morning as a preventative
4. Montelukast (Singulair) daily
The first-line therapy for mild-persistent asthma is:
1. High-dose montelukast
2. Theophylline
3. Low-dose inhaled corticosteroids
4. Long-acting beta-2-agonists
Monitoring a patient with persistent asthma includes:
1. Monitoring how frequently the patient has an upper respiratory infection (URI) during
treatment
2. Monthly in-office spirometry testing
3. Determining if the patient has increased use of his or her long-acting beta-2-agonist due to
exacerbations
4. Evaluating the patient every 1 to 6 months to determine if the patient needs to step up or
down in their therapy
Asthma exacerbations at home are managed by the patient by:
1. Increasing frequency of beta-2-agonists and contacting their provider
2. Doubling inhaled corticosteroid doses
3. Increasing frequency of beta-2-agonists
4. Starting montelukast (Singulair)
Patients who are at risk of a fatal asthma attack include patients:
1. With moderate persistent asthma
2. With a history of requiring intubation or ICU admission for asthma
3. Who are on daily inhaled corticosteroid therapy
4. Who are pregnant
Pregnant patients with asthma may safely use ________ throughout their pregnancy.
1. Oral terbutaline
